Source comparison
MK-677 vs CJC-1295/Ipamorelin Stack: Research Application Comparison
GH Secretion Pattern Continuous elevation over 24 hours; peak 90–120 min post-dose Pulsatile release mimicking endogenous rhythm; peak 60–90 min post-injection Stack preserves physiological pulsatility; MK-677 overrides natural rhythm Administration Route Oral
This comparison does not assign a generated winner or score.
- GH Secretion Pattern
- Continuous elevation over 24 hours; peak 90–120 min post-dose
- Pulsatile release mimicking endogenous rhythm; peak 60–90 min post-injection
- Stack preserves physiological pulsatility; MK-677 overrides natural rhythm
- Administration Route
- Oral (capsule/liquid); once daily
- Subcutaneous injection; 2–3x weekly
- MK-677 offers superior compliance in unsupervised settings
- Appetite Effect
- Significant increase in 70–85% of subjects
- Minimal to none (Ipamorelin is non-orexigenic)
- Stack eliminates confounding variable in body composition studies
- Water Retention Incidence
- 40% of subjects in first month; resolves weeks 6–8
- <15% incidence; mild when present
- Stack reduces subcutaneous fluid accumulation risk
- Receptor Desensitisation Risk
- Moderate after 12+ weeks continuous use
- Low (pulsatile dosing preserves sensitivity)
- Stack safer for protocols >16 weeks
- IGF-1 Elevation Magnitude
- 40–90% above baseline (dose-dependent)
- 60–110% above baseline at pulse peak
- Stack produces higher peak IGF-1; MK-677 sustains elevation
- Washout Period to Baseline
- 10–14 days for GH; 21–28 days for IGF-1
- 7–10 days for both markers
- Stack offers faster return to baseline physiology
- Cost per 30-Day Protocol
- Moderate (daily oral dosing)
- Higher (peptide synthesis + reconstitution materials)
- MK-677 more cost-effective for budget-limited trials